Inmagene Biopharmaceuticals
Biotechnology, 122 15th St, San Diego, California, 92014, United States, 51-200 Employees
Who is INMAGENE BIOPHARMACEUTICALS
Diseases do not recognize borders; why should drug innovation? We are a team of scientists and physicians driven by a shared commitment: to fulfill unmet medical needs for patients worldw...
Read More
-
Headquarters: 122 15th St, San Diego, California, 92014, United States
-
Date Founded: 2019
-
Employees: 51-200
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
Jonathan Wang
Email
Phone
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541715 |
Show More
Does something look wrong? Fix it. | View contact records from INMAGENE BIOPHARMACEUTICALS
Inmagene Biopharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Inmagene Biopharmaceuticals
Answer: Inmagene Biopharmaceuticals's headquarters are located at 122 15th St, San Diego, California, 92014, United States
Answer: Inmagene Biopharmaceuticals's official website is https://inmagenebio.com
Answer: Inmagene Biopharmaceuticals's revenue is Under $1 Million
Answer: Inmagene Biopharmaceuticals's SIC: 8731
Answer: Inmagene Biopharmaceuticals's NAICS: 541715
Answer: Inmagene Biopharmaceuticals has 51-200 employees
Answer: Inmagene Biopharmaceuticals is in Biotechnology
Answer: Inmagene Biopharmaceuticals contact info: Phone number: Website: https://inmagenebio.com
Answer: Diseases do not recognize borders; why should drug innovation? We are a team of scientists and physicians driven by a shared commitment: to fulfill unmet medical needs for patients worldwide by harnessing the most effective resources and efficient processes for drug development. We may take the brainchild of a scientist in one country to conduct proof of concept studies in another, and seamlessly transition to later clinical development globally. We coined our approach Borderless Innovation. Focused on immunology and inflammation, we are developing a new generation of drug candidates characterized by prolonged pharmacokinetic and pharmacodynamic effects as well as improved safety margins. This will potentially enable improved efficacy/safety profiles and dosing convenience. Leveraging cutting-edge technology, we have a rich pipeline consisting of four clinical-stage assets, targeting validated pathways, and multiple innovative preclinical candidates.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month